Precipio (PRPO) Projected to Post Earnings on Tuesday

Precipio (NASDAQ:PRPO) is projected to post its Q3 2026 results after the market closes on Tuesday, November 10th. Analysts expect the company to announce earnings of ($2.00) per share and revenue of $1.68 million for the quarter. Parties may visit the company’s upcoming Q3 2026 earnings report for the latest details on the call scheduled for Tuesday, November 10, 2026 at 5:00 PM ET.

Precipio (NASDAQ:PRPO) last announced its quarterly earnings results on Friday, August 14th. The biotechnology company reported ($0.12) EPS for the quarter, beating the consensus estimate of ($2.00) by $1.88. Precipio had a negative return on equity of 8.49% and a negative net margin of 4.47%. The company had revenue of $7.02 million for the quarter, compared to the consensus estimate of $1.68 million.

Precipio Stock Performance

Shares of NASDAQ:PRPO traded up $0.84 during trading on Tuesday, reaching $18.63. The stock had a trading volume of 7,592 shares, compared to its average volume of 58,235. The stock has a fifty day simple moving average of $24.33 and a two-hundred day simple moving average of $24.90. The company has a quick ratio of 1.56, a current ratio of 1.77 and a debt-to-equity ratio of 0.06. Precipio has a 52 week low of $17.79 and a 52 week high of $33.63. The firm has a market capitalization of $33.35 million, a price-to-earnings ratio of -28.73 and a beta of 1.45.

Analysts Set New Price Targets

Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of Precipio in a research report on Thursday, October 15th. One analyst has rated the stock with a Sell rating. According to data from MarketBeat, the stock has an average rating of “Sell”.

Precipio Company Profile

Precipio, Inc (NASDAQ: PRPO) is a biotechnology and medical diagnostics company focused on improving the diagnosis of cancer and other complex diseases. The company combines specialized pathology expertise with laboratory testing and diagnostic technologies intended to help physicians identify disease accurately and support treatment decisions.

Precipio provides clinical laboratory services in areas including hematopathology, cytogenetics and molecular diagnostics. Its work is particularly focused on blood cancers and other hematologic disorders, where accurate classification can be challenging.